Justyna Żubrowska

Dr. Justyna Żubrowska

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
RPRenata Pacholczak-Madej
Renata Pacholczak-Madej
AGAleksandra Grela-Wojewoda
Aleksandra Grela-Wojewoda
Miroslawa PüsküllüoğluMiroslawa Püsküllüoğlu
Miroslawa Püsküllüoğlu
JLJoanna Lompart
Joanna Lompart
MLManuela Las-Jankowska
Manuela Las-Jankowska
MZMarek Ziobro
Marek Ziobro
Nivolumab and ipilimumab combination became the first-line standard in advanced melanoma. We assessed its efficacy in a real-life study in Poland. In a one-year follow-up, we evaluated the medical records of 50 melanoma patients treated with that modality in five oncology centers. We recorded therapy outcomes and adverse events (AEs) after 3 and 12 months of therapy. At the first checkpoint, the disease control rate (DCR) was recorded in 58% (n = 29) of patients, but the same number of patients (n = 29, 58%) stopped immunotherapy due to disease progression (PD, n = 14, 48.3%), toxicity (n = 11, 37.9%) or death (n = 4, 13.8%). Among patients with DCR after the induction phase, 8 (27.6%) terminated due to toxicity, and 21 (72.4%) continued. However, at the 12-month checkpoint, only 14 patients (27% of all) were still receiving immunotherapy. In 7 (33.3%) it was discontinued due to PD (n = 2), toxicity (n = 2, 28.6% each), or death (n = 3, 42.9%). AEs occurred in 66.7% (n = 34) of patients; severe (grade 3 or 4) in half of them. Interestingly, those with AEs had an 80% lower risk of death (hazard ratio [HR] 0.2, 95% confidence interval [CI] 0.07–0.57, p = 0.001) and PD (HR 0.2, 95%CI 0.09–0.47, p < 0.0001). In the entire group of patients, after a 12-month follow-up, the median overall survival was not reached (NR, range: 6.8 months-NR) and progression-free survival was 6.3 (range: 3-NR) months. Our results demonstrate that combined immunotherapy is less effective in real-life than in pivotal trials. However, early responders will likely continue the therapy after a one-year follow-up. AEs occurrence might be a predictor of clinical effectiveness.

25 November 2025 in The Breast
Verified
Journal Article
Open access
RDRenata Duchnowska
Renata Duchnowska
KSKatarzyna Soter
Katarzyna Soter
KPKatarzyna Pogoda
Katarzyna Pogoda
JSJolanta Smok-Kalwat
Jolanta Smok-Kalwat
AGAleksandra Grela-Wojewoda
Aleksandra Grela-Wojewoda
JJJacek Jassem
Jacek Jassem
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first- and second-line treatments for hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). Real-world data (RWD) may inform the optimal use of these agents in routine practice. The multicenter, population-based POLiCDK study compared progression-free survival (PFS), second PFS, and overall survival (OS) in ABC patients with HR+/HER2- ABC treated with palbociclib (PAL), ribociclib (RIB), or abemaciclib (ABE) in first- or second-line ET settings at 16 Polish centers between September 2017 and January 2025. Analyses were stratified by endocrine sensitivity/resistance, and stabilized inverse probability of treatment weighting was used to balance baseline characteristics. Among 2063 patients (701 PAL, 968 RIB, 394 ABE), 1583 (76.7 %) received CDK4/6i in the first-line and 480 (23.3 %) in the second-line setting. Overall, 927 (44.9 %) had de novo ABC; 819 (39.7 %) were endocrine-naïve, 158 (8.9 %) primary resistant, and 808 (39.2 %) secondary resistant. Median follow-up was 35.9, 24.1, and 21.4 months for PAL, RIB, and ABE, respectively. In endocrine-naïve patients, PFS did not differ significantly between CDK4/6i combined with aromatase inhibitors (AIs). In secondary endocrine-resistant disease, RIB and ABE outperformed PAL with AI combinations, whereas outcomes with fulvestrant were similar. In second-line therapy, all three CDK4/6i showed comparable results. Adjusted hazard ratios confirmed these trends without consistent superiority of any single agent. Endocrine sensitivity/resistance and ET partner were major determinants of outcome with CDK4/6i plus ET in HR+/HER2- ABC, informing individualized treatment selection and sequencing.

9 December 2025 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
JŻJustyna Żubrowska
Justyna Żubrowska
MPMałgorzata Pieniążek
Małgorzata Pieniążek
APAnna Polakiewicz-Gilowska
Anna Polakiewicz-Gilowska
MMMiroslava Malejčíková
Miroslava Malejčíková
MHMiloš Holánek
Miloš Holánek
Miroslawa PüsküllüoğluMiroslawa Püsküllüoğlu
Miroslawa Püsküllüoğlu
Background: Metastatic metaplastic triple-negative breast cancer (mMpTNBC) is a rare, aggressive subtype with poor responsiveness to standard therapies. Sacituzumab govitecan (SG) is effective in metastatic TNBC (mTNBC), but data in mMpTNBC are limited to case reports. Patients and methods: This multinational, multicenter, retrospective case series was conducted within the CEBCC-102 real-world evidence project across 18 cancer centers. Female patients with histologically confirmed mMpTNBC treated with ≥ 2L SG outside of clinical trials in Poland, the Czech Republic and Slovakia between August 2021 and June 2025 were included. Clinical data, treatment outcomes, and adverse events (AEs) were collected from medical records and analysed. Results: Among 303 patients with mTNBC treated with SG in second and later lines within the CEBCC-102 project, 13 women (4.3%) had mMpTNBC and were included in this analysis. Median age was 58 years. PD-L1 CPS ≥ 10 was found in 83% of tested cases. Overall response rate was 36.4%, clinical benefit rate 45.5%, median progression-free survival 3.2 months and median overall survival 8.9 months. Neutropenia (N = 9, 69%) was the most common AE; no febrile neutropenia or treatment discontinuations due to toxicity occurred. Conclusions: This first international real-world series of SG in mMpTNBC shows clinically relevant activity and manageable toxicity, addressing a critical evidence gap and supporting further prospective studies, particularly in PD-L1–positive disease.

14 January 2026 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
JŻJustyna Żubrowska
Justyna Żubrowska
MPMałgorzata Pieniążek
Małgorzata Pieniążek
APAnna Polakiewicz-Gilowska
Anna Polakiewicz-Gilowska
IKIveta Kolářová
Iveta Kolářová
MMMiroslava Malejčíková
Miroslava Malejčíková
Miroslawa PüsküllüoğluMiroslawa Püsküllüoğlu
Miroslawa Püsküllüoğlu

12 January 2026 in The Breast
Verified
Journal Article
Open access
JŻJustyna Żubrowska
Justyna Żubrowska
MPMałgorzata Pieniążek
Małgorzata Pieniążek
APAnna Polakiewicz-Gilowska
Anna Polakiewicz-Gilowska
LRLenka Rušinová
Lenka Rušinová
RSRenata Soumarová
Renata Soumarová
Miroslawa PüsküllüoğluMiroslawa Püsküllüoğlu
Miroslawa Püsküllüoğlu
In heavily pretreated patients with metastatic triple-negative breast cancer (mTNBC), further systemic therapy offers limited benefit and increased toxicity. Recognizing the end-of-life (EOL) phase in time helps avoid overtreatment and ensure goal-concordant care. This study analyzed the interval between the last oncologist visit and death in pretreated women with mTNBC, as well as systemic therapy status, palliative care involvement and related factors. This multinational ambispective cohort study included women with mTNBC who received ≥2 lines of palliative systemic therapy and died between June 20, 2022 and June 20, 2025. Data from 17 centers in Poland, the Czech Republic and Slovakia were extracted from medical records. The primary endpoint was the interval between the final oncologist visit and death. 183 women with median age at death 53.6 years (28.6-86.5) were included. Patients had a median of 4 prior palliative chemotherapy lines (2-12) and the median interval from last oncologist visit to death was 17 days (0-410). At the final visit, 29.5 % continued systemic therapy and 49 % had prior palliative care involvement. Longer intervals were associated with PS 0-1 vs ≥ 2 (p = 0.005), while palliative care involvement had no significant effect (p = 0.849). The results highlight the need for earlier recognition of clinical decline and timely palliative care in mTNBC. Limiting non-beneficial systemic therapy near EOL supports symptom control, autonomy, and quality of life. Despite European efforts, including the Network of Expertise on Complex and Poor Prognosis Cancers, structured EOL planning remains a major gap.